谷甾醇血症的血小板蛋白质组学分析提示血小板减少由脂质紊乱驱动而非血小板异常
谷甾醇血症是一种罕见的常染色体隐性遗传病,由ABCG5或ABCG8功能障碍导致植物固醇肠道过度吸收。本文报告两个近亲家系,患者以慢性免疫性血小板减少症为主要表现,伴ABCG5隐性基因变异,血浆植物固醇显著升高,骨髓巨核细胞数和血小板生成素水平正常。饮食限制联合依折麦布治疗前后血小板蛋白质组学无显著变化,提示血小板减少并非由巨核细胞缺乏或血小板本身蛋白质组异常驱动。
要点
- 两个近亲家系患者以慢性免疫性血小板减少症为主要表现,检出ABCG5隐性基因变异。
- 患者无肝脾肿大,血小板生成素水平及骨髓巨核细胞数正常。
- 饮食限制联合依折麦布治疗前后血小板蛋白质组学无显著变化。
核心结论
- 数据提示谷甾醇血症患者的血小板减少既非由巨核细胞缺乏引起,也非由血小板本身蛋白质组异常驱动。
- 不能排除脂毒性在谷甾醇血症患者中对血小板有直接且特异性的影响。
研究设计与样本
- 报告两个无亲缘关系的近亲家系,患者以慢性免疫性血小板减少症为最突出特征。
- 通过计算机蛋白质结构分析和临床共分离确认ABCG5隐性基因变异与疾病相关。
- 纵向评估饮食限制联合依折麦布治疗前后血小板蛋白质组变化。
主要发现
- 两个家系均检出ABCG5隐性基因变异,经计算机蛋白质结构分析和临床共分离分析与疾病相关。
- 患者无肝脾肿大,血小板生成素水平及骨髓巨核细胞数正常。
- 代谢分析证实血浆植物固醇水平强烈升高。
- 饮食限制联合依折麦布治疗前后血小板蛋白质含量无显著变化。
临床怎么用
- 原文未据此给出推荐。
局限性
- 不能排除脂毒性在谷甾醇血症患者中对血小板有直接且特异性的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Sitosterolemia is a rare autosomal recessive genetic disorder in which patients develop hypercholesterolemia and may exhibit abnormal hematologic and/or liver test results. In this disease, dysfunction of either ABCG5 or ABCG8 results in the intestinal hyperabsorption of all sterols, including cholesterol and, more specifically, plant sterols or xenosterols, as well as in the impaired ability to excrete xenosterols into the bile. It remains unknown how and why some patients develop hematologic abnormalities. Only a few unrelated patients with hematologic abnormalities at the time of diagnosis have been reported. Here, we report on 2 unrelated pedigrees who were believed to have chronic immune thrombocytopenia as their most prominent feature. Both consanguineous families showed recessive gene variants in ABCG5, which were associated with the disease by in silico protein structure analysis and clinical segregation. Hepatosplenomegaly was absent. Thrombopoietin levels and megakaryocyte numbers in the bone marrow were normal. Metabolic analysis confirmed the presence of strongly elevated plasma levels of xenosterols. Potential platelet proteomic aberrations were longitudinally assessed following dietary restrictions combined with administration of the sterol absorption inhibitor ezetimibe. No significant effects on platelet protein content before and after the onset of treatment were demonstrated. Although we cannot exclude that lipotoxicity has a direct and platelet-specific impact in patients with sitosterolemia, our data suggest that thrombocytopenia is neither caused by a lack of megakaryocytes nor driven by proteomic aberrations in the platelets themselves.
引用
- Del Castillo J, Tool ATJ, van Leeuwen K, et al. Platelet proteomic profiling in sitosterolemia suggests thrombocytopenia is driven by lipid disorder and not platelet aberrations. Blood Adv. 2024. PMID: 38513134. doi:10.1182/bloodadvances.2023012018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。